Estrace (estradiol) / AbbVie - LARVOL DELTA

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Jul 2026 ➔ Dec 2026

Trial completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR

Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse (clinicaltrials.gov) - P4 | N=7 | Terminated | Sponsor: The University of Texas Medical Branch, Galveston | N=10 ➔ 7

Enrollment change • Women's Health

Trends in Prescription Cost Savings for Vaginal Estrogen. (PubMed, Urogynecology (Phila)) - "While significant price variations for prescriptions were seen on a regional level within zip codes and between pharmacies, notable price savings were consistently seen with CPD and GoodRx, offering a solution to the financial strain that these prescriptions may impose."

HEOR • Journal • Women's Health

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Washington | Trial completion date: Jun 2026 ➔ Jun 2028 | Trial primary completion date: Mar 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Estrogen and Fear in PTSD (clinicaltrials.gov) - P3 | N=64 | Completed | Sponsor: The University of Texas Health Science Center, Houston | Recruiting ➔ Completed | Trial completion date: Jul 2025 ➔ Dec 2024 | Trial primary completion date: Jul 2025 ➔ May 2024

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Washington | Suspended ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Estradiol Plus Olaparib for Breast Cancer (PHOEBE) (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Mary D Chamberlin | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

VITAL-E: Silicone Gel Vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: Stratpharma AG | Trial completion date: Jun 2024 ➔ Nov 2025 | Trial primary completion date: Jun 2024 ➔ Nov 2025

Head-to-Head • Trial completion date • Trial primary completion date • Women's Health

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Suspended | Sponsor: University of Washington | Recruiting ➔ Suspended

Metastases • Trial suspension • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome (clinicaltrials.gov) - P4 | N=152 | Recruiting | Sponsor: Walter Reed National Military Medical Center | Trial completion date: Jan 2024 ➔ Jan 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2026

Trial completion date • Trial primary completion date • Overactive Bladder

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: Mayo Clinic | Enrolling by invitation ➔ Active, not recruiting | N=38 ➔ 5

Enrollment change • Enrollment closed • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR

Estrogen and Fear in PTSD (clinicaltrials.gov) - P3 | N=80 | Recruiting | Sponsor: NYU Langone Health | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=38 | Enrolling by invitation | Sponsor: Mayo Clinic | Trial completion date: Apr 2024 ➔ Jul 2026 | Trial primary completion date: Apr 2024 ➔ Jul 2026

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR

Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice. (PubMed, Drug Deliv Transl Res) - "Further, we demonstrate compatibility of the estradiol NS with vaginal bacteria in vitro. We demonstrate that a Pluronic F127-coated estradiol NS may be a viable option for the treatment of post-menopausal vaginal atrophy."

Journal • Preclinical • Vaginal Atrophy • Women's Health

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections (clinicaltrials.gov) - P4 | N=111 | Recruiting | Sponsor: University of California, Irvine

Adherence • New P4 trial • Infectious Disease • Nephrology

Vaginal Estrogen Prescribing and Cost Trends Among Medicare Part D Beneficiaries. (PubMed, Urogynecology (Phila)) - "Vaginal estrogen claims, beneficiaries, and total expenditures across all provider types have decreased from 2016 to 2020. However, spending per beneficiary and VE claims have increased. Our data suggest that utilization and accessibility of vaginal estrogen may be influenced, in part, by cost."

Journal • Medicare • Reimbursement • US reimbursement • Breast Cancer • Obstetrics • Oncology • Solid Tumor

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: University of Washington | Trial completion date: Mar 2025 ➔ Jun 2026

Metastases • Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=38 | Enrolling by invitation | Sponsor: Mayo Clinic | Recruiting ➔ Enrolling by invitation

Enrollment status • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR

Estradiol Plus Olaparib for Breast Cancer (PHOEBE) (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Mary D Chamberlin | Initiation date: Feb 2024 ➔ May 2024

Metastases • Trial initiation date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse (clinicaltrials.gov) - P4 | N=10 | Terminated | Sponsor: The University of Texas Medical Branch, Galveston | Trial completion date: Dec 2024 ➔ Dec 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: May 2024 ➔ Dec 2023; Collaborator moved and not able to recreate full study team

Trial completion date • Trial primary completion date • Trial termination • Women's Health

Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: University of Alabama at Birmingham | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Jan 2024 ➔ Jan 2026

Trial completion date • Trial primary completion date • Obstetrics • Sexual Disorders • Urinary Incontinence • Urology

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: University of Washington

Metastases • New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER) (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Dartmouth-Hitchcock Medical Center

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER

Estradiol Plus Olaparib for Breast Cancer (PHOEBE) (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Dickinson

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2